Mukherjee, S.; Pattnaik, H.; Sonti, S.; Ramesh, M.; Jain, P.; Ramirez, R.A.; Fountzilas, C.; Vadehra, D.; Attwood, K.; Iyer, R.
Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown Origin. Cancers 2025, 17, 224.
https://doi.org/10.3390/cancers17020224
AMA Style
Mukherjee S, Pattnaik H, Sonti S, Ramesh M, Jain P, Ramirez RA, Fountzilas C, Vadehra D, Attwood K, Iyer R.
Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown Origin. Cancers. 2025; 17(2):224.
https://doi.org/10.3390/cancers17020224
Chicago/Turabian Style
Mukherjee, Sarbajit, Harsha Pattnaik, Sahithi Sonti, Mrinalini Ramesh, Prantesh Jain, Robert A. Ramirez, Christos Fountzilas, Deepak Vadehra, Kristopher Attwood, and Renuka Iyer.
2025. "Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown Origin" Cancers 17, no. 2: 224.
https://doi.org/10.3390/cancers17020224
APA Style
Mukherjee, S., Pattnaik, H., Sonti, S., Ramesh, M., Jain, P., Ramirez, R. A., Fountzilas, C., Vadehra, D., Attwood, K., & Iyer, R.
(2025). Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown Origin. Cancers, 17(2), 224.
https://doi.org/10.3390/cancers17020224
